ReviewMedicine2025
Clinical characterization of IRF2BPL mutation: Case series and review of the literature.
Review in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleIRF2BPL is an intronless gene localized to chromosome 14q24.3 that encodes an interferon regulatory factor 2 binding-like protein. In this study, we reviewed the literature on mutations in the IFR2BPL gene. In addition, we report a case of Neurodevelopmental Disorder with Degeneration, Abnormal Movements, Loss of Speech and Seizures (NEDAMSS) caused by a mutation in the IFR2BPL gene. The aim of this report is to increase clinicians' awareness of such clinical cases. PATIENT CONCERNS: In this report, we discuss the case of a 15-year-old male patient. The patient started with epilepsy and dystonia and was treated with antiepileptic seizure medication, then he was admitted to our hospital for recurrent seizures of epilepsy and dystonia, and the diagnosis of NEDAMSS was confirmed by whole exome genetic testing. DIAGNOSES: Exome-wide genetic testing confirmed the diagnosis of NEADMSS due to IRF2BPL.
interventionsExome-wide genetic testing reveals mutations in the IFR2BPL gene. OUTCOMES: Symptoms improved from before after antiepileptic seizure medication combined with drugs to improve dystonia. LESSONS: We have come across a case of recurrent seizures of epilepsy and dystonia due to a mutation in the IFR2BPL gene for which no definitive treatment has been found. Recently, several studies have led to the discovery of a new drug for the treatment of NEDAMSS. CuII (atsm) (copper II diacetylbis(4-methylaminouracil)) (CuATSM) is a small-molecular-weight drug that can be administered orally and then used in the human body. The literature suggests that the underlying mechanism of CuATSM involves the restoration of mitochondrial function, including correction of the mitochondrial differentiation and mislocalization observed in cells from NEDAMSS patients, but extensive trials are needed to demonstrate its efficacy in IFR2BPL-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.